C&AG report: Nama ‘got best price’ for portfolio

Nama has insisted it got the best price possible for its controversial Northern Ireland property portfolio.

C&AG report: Nama ‘got best price’ for portfolio
Thu, 15 Sep, 2016 - 01:00
Brian Hutton

Ireland’s bad bank said the £1.3bn sale to US investment fund Cerberus two years ago was “the best achievable result”.

As an official report flagged concerns about a discount on the sale, Frank Daly, chairman of the toxic assets agency, said the so-called Project Eagle portfolio would not reach even near that price today.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

CONNECT WITH US TODAY

Whatsapp logo

WHATSAPP

Newsletter logo

NEWSLETTERS

Notification logo

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

Explosion at Donegal service station Planning granted for new petrol station next to site of Creeslough tragedy
Michael Lyster remembered as ‘magic in human form’ at emotional memorial service Michael Lyster remembered as ‘magic in human form’ at emotional memorial service
AI prompt chat bot. Search website to generate data, text or image. Man using computer with artificial intelligence app. Virtual Mental health experts issue warning over AI 'therapy'
CourtsNamaproject eaglePlace: Northern IrelandPlace: IrelandPlace: USPlace: DublinPlace: LondonPerson: NamaPerson: Frank DalyPerson: DalyOrganisation: C&AGOrganisation: CerberusOrganisation: CA&GOrganisation: NAMAOrganisation: Project EagleOrganisation: KPMGOrganisation: Eastdil SecuredOrganisation: Cushman & WakefieldOrganisation: Lazard
<p>Sodium valproate, manufactured by Sanofi and sold as Epilim, has been linked to a high risk of serious injury for babies in the womb. File picture</p>

Three more children settle Epilim sodium valproate cases

READ NOW

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Latest

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited